ArticleFrontiers in oncology2025
The prognostic significance of incomplete hematological recovery in pediatric patients with low/intermediate risk AML and negative MRD after induction 1.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pediatric acute myeloid leukemia (AML) accounts for approximately 25% of childhood hematologic malignancies. Outcomes have markedly improved, especially in low-risk and intermediate-risk patients, with overall survival (OS) rates approaching 80-85%. Prognosis is primarily determined by cytogenetic/molecular risk and minimal residual disease (MRD) status following induction therapy. While complete remission (CR) traditionally requires morphologic clearance of leukemia with full hematologic recovery, some patients achieve morphologic remission with incomplete recovery (CRi). Although adult studies associate CRi with poor prognosis, its relevance in MRD-negative pediatric AML remains unclear. This study evaluates the prognostic significance of hematologic recovery in MRD-negative, low/intermediate-risk pediatric AML. Methods: We conducted a retrospective analysis of 120 pediatric AML patients treated at CCHE-57357 between 2012 and 2020 who achieved MRD negativity (<0.1% by 8-10 color flow cytometry) after Induction I. Risk stratification followed WHO/ELN guidelines. For exploratory purposes, intermediate-risk patients with MRD <0.1% were reclassified as "MRD-defined low risk." Patients were categorized by hematologic recovery: CR (ANC ≥1000/µL, platelets ≥100,000/µL), partial hematological recovery (CRh) (ANC ≥500/µL and/or platelets ≥50,000/µL), and CRi (ANC 500/µL and/or platelets <50,000/µL). Outcomes included OS, relapse-free survival (RFS), and event-free survival (EFS). Results: Among 120 patients (median age 8.5 years), 25 (21%) achieved CR, 17 (14.3%) CRh, and 78 (64.7%) CRi. CRi patients had numerically lower 5-year OS (63.3%) compared to CRh (76%) and CR (71.8%), though differences were not statistically significant. Platelet recovery alone (complete Platelet recovery (CRp) vs incomplete platelet recovery (CRip) showed a trend toward prognostic relevance (5-year OS: 73.3% vs 57.1%), also non-significant. Infectious complications were common: six sepsis-related deaths occurred in the low-risk group and four in the standard-risk group, with ICU admissions disproportionately higher in standard-risk patients (12 vs 1). CRi patients experienced longer hospital stays and required more transfusion support. Conclusion: In MRD-negative pediatric AML, incomplete hematologic recovery did not significantly predict inferior survival, though trends suggest potential prognostic value-particularly in low-risk patients. CRi may reflect treatment-related toxicity or infectious complications rather than residual disease. These findings support a more nuanced interpretation of remission depth and highlight the need for larger, multi-institutional studies incorporating molecular risk refinement and clinical context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.